A phase II study comparing oral S-1 + 24-hour infusion of CPT-11 +bevacizumab with FOLFIRI+bevacizumab for metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-08 收录
官方服务：
资源简介：
Interventions: standard therapy group (FOLFIRI+bevacizumab) trial therapy arm (Oral S-1+24-hour infusion of CPT-11+bevacizumab) Primary outcome(s): 1 year progression-free survival Study Design: Parallel Randomized
创建时间：
2013-12-15
